Movement Alert｜MEDBOT-B Rises 5.17% in Regular Trading, First Half-Year Profit Combined With Broker Buy Rating Fuels Valuation Recovery

Market Focus08-04

On August 4, MEDBOT-B rose 5.17% in regular trading, trading at HK$22.4/share, with turnover of HK$70.14 million.

On the news front, Dahua Capital recently initiated coverage with a Buy rating and a HK$29 target price, citing the company's 5G remote surgery capabilities and global expansion, projecting a 73.8% revenue CAGR from 2025 to 2028. This follows the company's positive profit alert issued in late July, forecasting its first-ever half-year net profit of RMB 28-40 million, versus a net loss of RMB 115 million in the prior-year period.

Fundamentally, the turnaround was driven by revenue surging 200%-230% year-over-year, with the Toumai laparoscopic surgical robot achieving overseas revenue growth exceeding 450%. Global commercial installations have surpassed 200 units with orders exceeding 300 units across more than 60 countries. Gross margin improved by over 15 percentage points, while operating expense ratios continued to decline, reflecting enhanced operational efficiency.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1142670284?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-04 10:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142670284","market":"hk","top_or_hot":-1,"title":"Movement Alert｜MEDBOT-B Rises 5.17% in Regular Trading, First Half-Year Profit Combined With Broker Buy Rating Fuels Valuation Recovery","media":"Market Focus","content":"<p><p>On August 4, MEDBOT-B rose 5.17% in regular trading, trading at HK$22.4/share, with turnover of HK$70.14 million.</p><p>On the news front, Dahua Capital recently initiated coverage with a Buy rating and a HK$29 target price, citing the company's 5G remote surgery capabilities and global expansion, projecting a 73.8% revenue CAGR from 2025 to 2028. This follows the company's positive profit alert issued in late July, forecasting its first-ever half-year net profit of RMB 28-40 million, versus a net loss of RMB 115 million in the prior-year period.</p><p>Fundamentally, the turnaround was driven by revenue surging 200%-230% year-over-year, with the Toumai laparoscopic surgical robot achieving overseas revenue growth exceeding 450%. Global commercial installations have surpassed 200 units with orders exceeding 300 units across more than 60 countries. Gross margin improved by over 15 percentage points, while operating expense ratios continued to decline, reflecting enhanced operational efficiency.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜MEDBOT-B Rises 5.17% in Regular Trading, First Half-Year Profit Combined With Broker Buy Rating Fuels Valuation Recovery</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜MEDBOT-B Rises 5.17% in Regular Trading, First Half-Year Profit Combined With Broker Buy Rating Fuels Valuation Recovery\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-04 10:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 4, MEDBOT-B rose 5.17% in regular trading, trading at HK$22.4/share, with turnover of HK$70.14 million.</p><p>On the news front, Dahua Capital recently initiated coverage with a Buy rating and a HK$29 target price, citing the company's 5G remote surgery capabilities and global expansion, projecting a 73.8% revenue CAGR from 2025 to 2028. This follows the company's positive profit alert issued in late July, forecasting its first-ever half-year net profit of RMB 28-40 million, versus a net loss of RMB 115 million in the prior-year period.</p><p>Fundamentally, the turnaround was driven by revenue surging 200%-230% year-over-year, with the Toumai laparoscopic surgical robot achieving overseas revenue growth exceeding 450%. Global commercial installations have surpassed 200 units with orders exceeding 300 units across more than 60 countries. Gross margin improved by over 15 percentage points, while operating expense ratios continued to decline, reflecting enhanced operational efficiency.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02252","symbol_name":"微创机器人-B","start_time":0,"source_url":"","article_id":"1142670284","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142670284","pubTimestamp":1785810095,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 4, MEDBOT-B rose 5.17% in regular trading, trading at HK$22.4/share, with turnover of HK$70.14 million.On the news front, Dahua Capital recently initiated coverage with a Buy rating and a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02252":"微创机器人-B"},"translate_title":"走势警报|MEDBOT-B 常规交易上涨 5.17%，上半年利润加上经纪商买入评级推动估值复苏","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02252":1},"content_text":"On August 4, MEDBOT-B rose 5.17% in regular trading, trading at HK$22.4/share, with turnover of HK$70.14 million.On the news front, Dahua Capital recently initiated coverage with a Buy rating and a HK$29 target price, citing the company's 5G remote surgery capabilities and global expansion, projecting a 73.8% revenue CAGR from 2025 to 2028. This follows the company's positive profit alert issued in late July, forecasting its first-ever half-year net profit of RMB 28-40 million, versus a net loss of RMB 115 million in the prior-year period.Fundamentally, the turnaround was driven by revenue surging 200%-230% year-over-year, with the Toumai laparoscopic surgical robot achieving overseas revenue growth exceeding 450%. Global commercial installations have surpassed 200 units with orders exceeding 300 units across more than 60 countries. Gross margin improved by over 15 percentage points, while operating expense ratios continued to decline, reflecting enhanced operational efficiency.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1142670284","isCrawlerRequest":true}